Pudong New Area, China

Huiting Xu

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Huiting Xu. Retrieved from https://idiyas.com/inventor/huiting-xu

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 8.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Huiting Xu and His Patent on Human IL-33 Antibodies.

Introduction

Huiting Xu is an inventor associated with Pudong New Area, China. The available information lists 1 patent under his name and connects him with Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Latest Patents

Xu is named in the patent “Human IL-33 Antibodies, Preparation Method and Conjugates Thereof and Method of Use Thereof for Treatment.” The invention concerns human IL-33 antibodies, their preparation and conjugates, and methods of use for treatment.

Career Highlights

The listed patent reflects Xu’s work in pharmaceutical research and antibody-related inventions. The available details do not specify his role, employment dates, or other career milestones.

Collaborations

Zhenping Zhu and Wei Guo are identified as Xu’s coworkers. Their names are also associated with the collaborative context of his pharmaceutical work.

Conclusion

Huiting Xu’s recorded invention focuses on human IL-33 antibodies and their potential therapeutic use, reflecting his connection to pharmaceutical innovation at Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…